The verdict
Our read at a glance.
Whether a partial opioid agonist that many people use to get off stronger opioids is a harm-reduction tool or simply another dependence.
- The signal
- The research is more serious than the retail context suggests. Registered trials have examined single ascending doses of kratom in healthy adults with opioid experience, pharmacokinetic interaction studies with oxycodone and with kava, mitragynine formulations for pain, and real-world momentary assessment studies with product assays. The review literature covers clinical pharmacology, abuse potential, dependence and treatment options, and the genuine controversies in diagnosing kratom use disorder. Two things emerge consistently: mitragynine is a partial mu-opioid agonist with a ceiling on respiratory depression that differs from classical opioids, and dependence with a withdrawal syndrome is real in regular users.
- The unknown
- Whether the risk profile established for leaf material transfers to the concentrated 7-hydroxymitragynine products now dominating retail. 7-OH is a far more potent mu agonist, and treating those products as equivalent to traditional leaf is the central error in the current debate.
- Our read
- The most nuanced entry in this batch, and the one where a flat answer would be dishonest. The pharmacology is genuinely different from classical opioids and the harm-reduction claim is not absurd. But the market has changed underneath the research: the products being sold now are concentrated 7-OH, which is not what the traditional-use literature is about, and the science has not caught up with what is on the shelf.
The mechanism
How it works.
The kratom leaf contains dozens of alkaloids, and the two that matter are mitragynine, which is most abundant, and 7-hydroxymitragynine, which is present in small amounts in the leaf but is far more potent. Both act at the mu-opioid receptor as partial agonists, and they are biased agonists: they activate G-protein signalling with relatively little beta-arrestin recruitment, which is the pathway most associated with respiratory depression. That bias is the pharmacological basis for the claim that kratom carries a lower overdose risk than classical opioids, and it is a real difference rather than folklore. Mitragynine also has adrenergic and serotonergic activity, which explains the stimulant-like effect at low doses that users describe before the opioid-like effects appear at higher ones. The critical practical point is potency: concentrating 7-hydroxymitragynine changes the product from a weak partial agonist to something much closer to a conventional opioid.
Safety & regulatory boundary
The consequential part.
Not approved for any medical use and not a lawful dietary supplement ingredient. FDA has warned against it and has moved specifically against concentrated 7-hydroxymitragynine products; several states and countries ban it outright. Documented harms include dependence and withdrawal, hepatotoxicity, seizures, and deaths in which kratom was detected - most, though not all, alongside other substances. Product contamination with salmonella and heavy metals has been documented, and alkaloid content varies enormously between products.
What's next
What we're watching.
Regulatory action on 7-OH concentrates specifically, and the outcome of the controlled dosing and interaction studies now running.
Context
Why this is discussed.
It is used at scale for pain, energy and self-managed opioid withdrawal, it is legal in most of the United States, and the debate about it is unusually polarised.
The evidence base
20 cited references.
Registered trials8
ClinicalTrials.gov · PHASE1 · NOT_YET_RECRUITING · 2026-09-01
ClinicalTrials.gov · PHASE3 · NOT_YET_RECRUITING · 2026-07-01
ClinicalTrials.gov · PHASE1 · NOT_YET_RECRUITING · 2026-09
ClinicalTrials.gov · EARLY_PHASE1 · RECRUITING · 2023-06-01
ClinicalTrials.gov · NA · RECRUITING · 2026-05-04
ClinicalTrials.gov · NA · RECRUITING · 2026-03-07
ClinicalTrials.gov · PHASE1 · COMPLETED · 2023-08-16
ClinicalTrials.gov · COMPLETED · 2022-07-20
Indexed literature (PubMed)12
Sethi R et al. · Prim Care Companion CNS Disord · 2020
McCurdy CR et al. · Expert Rev Clin Pharmacol · 2024
Bin Abdullah MFIL · Curr Drug Targets · 2020
Smith KE et al. · Curr Psychiatry Rep · 2024
Warner ML et al. · Int J Legal Med · 2016
Sanderson M et al. · CMAJ · 2019
Weiss ST et al. · J Addict Med · 2021
Alsbrook S et al. · Pharm Biol · 2025
Gorelick DA · Psychiatr Clin North Am · 2022
Nayak LJ et al. · Gastroenterology · 2021
Schmitt J et al. · Am J Forensic Med Pathol · 2021
Huestis MA et al. · Molecules · 2024
Keep reading